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Clinical Features and Outcome of Surgery in 30 Patients with Acromegaly
A. Chandna, N. Islam, A. Jabbar, L. Zuberi, N. Haque
Endocrinology Section, Department of Medicine, Aga Khan University Hospital, Karachi.
Abstract
Objective: To assess the surgical outcome of hypophysectomy in acromegalic patients, differences in response
to surgery in micro and macroadenoma and the development of associated hormonal deficiency after surgery.
Methods: Retrospective analysis of charts of acromegalic patients who were operated upon at Aga Khan
University Hospital, Karachi, was done. Information regarding presentation, laboratory data, radiological assess-
ment, details of surgery and postoperative outcome was recorded. Surgical outcome was classified depending
on the degree of disease control after surgery as biochemical cure, remission and treatment failure. 
Results: Out of 30 patients, eighteen (60%) were males and 12 (40%) females with mean age at the time of
diagnosis 35.6± 10.4 years. The mean duration of symptoms was 3.2± 2.4 years. Twenty-five patients had
macroadenoma and five had microadenoma. Preoperative mean GH level was 42.4ng/ml with range of 2.5 to
534 ng/ml. Following surgery, 13 had biochemical cure, 4 were in remission and 13 failed to respond. The out-
come in microadenoma was better than in macroadenoma i.e. 100% vs. 32%. Preoperatively four patients had
panhypopituitarism with additional six patients(20%) developing hypopituitarism  postoperatively.
Conclusion: Our study showed that acromegaly was seen at a much earlier age, outcome of surgery was com-
parable to other international studies and postoperative panhypopituitarism was seen in significant number of
patients. The outcome in microadenoma was better than in macroadenoma but the number of patients seen with
microadenoma was small (JPMA 54:315;2004). 
Introduction
Acromegaly is an uncommon disease with an annu-
al incidence of 3/million and an estimated prevalence of
40/million population.1 In the majority of patients it is
caused by a pituitary adenoma and is associated with signif-
icantly shortened life span that is not due to direct effect
from the tumour but results from cardiovascular, respirato-
ry and cerebrovascular complications.2 In addition there is
an increased risk of malignancy.3 Acral growth, coarsened
facial features and soft tissue swelling are the most common
symptoms of acromegaly4 which develop slowly over time
so the diagnosis is delayed for years.5
Optimal therapy should be aimed at alleviating
symptoms, reducing tumour bulk, preventing regrowth and
reducing mortality without the development of hypopitu-
itarism.6 Surgery remains the treatment of choice as this
offers a rapid permanent reduction of Growth hormone
(GH) level and relief from the mass effect of the tumour. In
those patients in whom operative cure is not achieved,
radiotherapy and/or medical therapy are useful treatment
modalities. Biochemical cure is considered as GH level<2.5
ng/ml, normal IGF level and post Oral Glucose Tolerance
Test(OGTT), GH level<1 ng/ml.7,8 Using strict criteria for
cure, rate as high as 67% have been reported for surgery
alone.9 Outcome of surgery is inversely correlated to preop-
erative GH level10, tumour size11 and tumour stage.12 
We retrospectively analyzed the medical records of
patients with acromegaly who were operated upon, to asses
the  surgical  outcome  of  hypophysectomy,  the difference 
in outcome of microadenoma and macroadenoma and
development of postoperative hormonal deficiencies.
Patients and Methods
A retrospective review of medical records was per-
formed on 45 patients with the diagnosis of Acromegaly
who presented at Aga Khan University Hospital between
1989-2002.  
Ten patients who had had previous pituitary surgery
or irradiation were excluded. Five patients who did not
undergo surgery were also excluded.Information regarding
presentation, investigations like hormonal and radiological
assessment, details of surgery and postoperative outcome
were recorded.
All patients exhibited signs and symptoms of
acromegaly with confirmation of diagnosis by elevated
baseline GH levels and OGTT suppression test. An Oral
Glucose Tolerance Test was performed by fasting the patient
overnight and then taking a 0900 h basal blood sample. The
patient was then given an oral dose of 75 g of glucose.
Blood samples were collected every 30 min for 120 min and
were analyzed for GH and glucose levels.
Preoperative MRI/CT scan were done and tumours
were classified into macro (>10 mm) or microadenomas
(<10 mm). 
The postoperative cure was assessed by measuring
random GH levels in most of the patients and postoperative
OGTT suppression test was done in five patients. The hor-
monal assessment was done within two weeks of surgery.
Biochemical cure was considered to be achieved when there
was suppression of random GH level of <2.5 ng/ml or
serum GH <1 ng/ml after OGTT, remission when GH level
was between 2.5 and 5.0 ng/ml and failure to surgical treat-
ment when persistently elevated random GH levels or fail-
ure to suppress/paradoxical rise of GH on OGTT.7,13
Postoperative workup also included repeat MRI scan
of pituitary and hormonal assessment for pituitary insuffi-
ciency. GH measurement was done using Immulite® 2000
analyzer(Diagnostic Product Corp. Ltd.) with chemilummi-
nescence assay. The normal adult range for this kit  was
0.06-5.0 ng/ml.
Statistical Method
Results were expressed as mean + standard devia-
tion, median with range for all continuous variables (e.g,
age, duration of symptoms etc.) and number (percentage)
for categorical data (e.g, gender, surgical outcome etc.).
Univariate analysis was performed by using the Pearson
Chi-square test, Fisher Exact test, and Mann Whitney U-test
whenever appropriate. A p-value <0.05 was considered as
statistically significant. All p-value were two sided. The
Statistical package for social science SPSS (Release 10.0.5,
standard version, copyright © SPSS; 1989-99) was used for
data analysis.
Results
Patient population
Out of 30 patients, eighteen were males (60%) and
12 were females (40%). The mean age of patients at the time
of diagnosis was 35.6 ± 10.4 years (range, 16-52) (Figure
1). The mean duration of symptoms reported by the patient
at the time of diagnosis was 3.2 ± 2.4 years.  
The majority of tumours were macroadenoma, i.e.
25 patients (83%) but 5 had microadenoma (17%). Out of
25 macroadenamas, 19 had suprasellar extension and 12
were with optic chiasmal compression. Cavernous sinus
involvement was present in 3 patients and sellar floor
destruction with sphenoid sinus involvement in 3 patients. 
Preoperative mean GH level was 42.4ng/ml with
range of 2.5 to 534 ng/ml. In patients with microadenoma
GH level was between 4.5 - 17.5ng/ml whereas higher lev-
els were seen with macroadenoma. Preoperative OGTT sup-
pression was done in 10 patients and was found to be abnor-
mal in all.
Figure 1. Age distribution.
Table 1. Summary of characteristics of adenomas.
Characteristics MRI size of adenoma p-value
Macro Micro
(n=25) (n=5)
Pre-op GH level 30.4 (5.8-534) 12.5 (5.3-19) 0.015
Post-op GH level 5.7 (0.5-213) 0.9 (0.4-1.9) 0.021
Age (years) 31 (16-52) 45 (37-51) 0.016
Duration of
symptoms (years) 2 (0.5-10) 5 (0.3-9) 0.552
abnormal in all.
Out of 30 patients who underwent surgery, thirteen
patients had serum GH level of <2.5 ng/ml, four had levels
between 2.5-5 whereas 13 had elevated levels.
Postoperative OGT was done in 5 patients and no suppres-
sion of GH was there in four cases. Thus 13 had biochemi-
cal cure, 4 patients were in remission and 13 failed to
respond to surgical treatment( Table 2). The outcome in
microadenoma was better than in macroadenoma i.e., 100%
vs. 32%.
Preoperatively four patients had panhypopituitarism,
who did not recover from suppression after surgery.
Postoperatively, additional six patients (20%) had panhy-
popituitarism.
Discussion
Acromegaly is a slowly progressive disease charac-
terized by disfigurement and disability.14 Mortality in
untreated acromegalics is probably two to three times that of
healthy people.1,15 The observation that this increased mor-
tality is decreased to normal in a population of cured
acromegalics16 highlights the importance of achieving a
biochemical cure. Treatment by surgery not only offers the
advantage of an immediate decline of GH levels17 but also
relieves the local pressure effects, reducing the systemic
morbidity and normalizing the mortality. Surgery thus
remains the first line treatment modality with adjuvent ther-
apy consisting of radiotherapy and/or medical treatment. 
We retrospectively analyzed the clinical features and
outcome of transsphenoidal hypophysectomy, in patients
with acromegaly. There was male preponderance i.e. 60%
whereas other studies suggested nearly equal sex distribu-
tion.18,19 We found that the mean age was lower than that
reported in other studies i.e., 35.6 years as compared to
46.320 and 5018 years. 
The changes in appearance occur insidiously, so that
very often the disorder is diagnosed only when a new physi-
cian replaces the usual doctor and sees the patient for the
first time or when photographs of the patient taken over a
number of years are collected together.5 Hence there can be
a delay of 5-8 years18,19 in the diagnosis. From the charts
reviewed it was noted that the mean duration of symptoms
reported by the patients, was 3.3 ± 2.4 years (Table 1). This
comparatively short duration can either be because of more
aggressive disease but more likely this can be due to delay
on part of the patient in observing the subtle changes in the
Figure 2. GH levels in microadenoma. Figure 3. GH levels in macroadenoma.
Table 2. Surgical outcome.
Outcome of surgery
Cure Remission Failure Total
Pre-op MRI Macro 8 (32%) 4 (16%) 13 (52%) 25 (100%)
size of adenoma Micro 5 (100%) 5 (100%)
Total 13 (43.3%) 4 (13.3%) 13 (43.3%) 30 (100%)
on part of the patient in observing the subtle changes
in the features until they become very obvious.
Majority of patients had macroadenoma which is in
accordance with literature.16,18 It has been suggested that
young patients with acromegaly generally have larger and
more rapidly growing tumours at the time of diagnosis than
older patients.21 Our data also showed that macroadenoma
was seen in younger age group i.e. between 16-52 years
with median of 31 years, whereas in case of microadenoma
median age was 45 (Table 1). 
The definition of cure of acromegaly has been a mat-
ter of controversy. Till 1980s, a post therapeutic GH level
<5 ng/ml was considered to be consistent with disease
cure22-24 but in the beginning of mid 1990s, a more stringent
definition of cure has been used because analyses of long
term outcomes have shown that mortality rates among treat-
ed acromegalics do not reach those of the normal population
until GH levels drop below 2.5 ng/ml.25 It was seen that
with levels less than 5 ng/ml, there was recurrence of the
disease in most of patients but with levels less than
2.5ng/ml, the long term cure rate went upto 97%.26
Accordingly using the older criteria, many patients will
experience remission of their disease rather than a cure.13
According to the consensus statement issued in
19997,  the cure is said to be achieved when circulating IGF-
I is reduced to an age-adjusted normal range and nadir GH
after an oral glucose load is less than 1 µg/L.
In our study, 13 patients had GH level of <2.5 ng/ml
and only 5 of them underwent dynamic study with OGTT
with one patient having suppression of GH level. So there
was a biochemical cure rate of 43.3% (Table 2) which is the
same as reported by Sheaves et al26 using the strict criteria.
IGF 1 level measurement is not available in our country.
Thus random GH levels and OGTT suppression test are
only available tests to asses treatment outcome.
The study had a number of limitations. It was a retro-
spective analysis of the charts, most of the patients followed
up with neurosurgeons rather than endocrinologists, unavail-
ability of IGF 1 level measurement and only few of them had
dynamic testing done to asses the cure.
The surgical outcome in microadenoma was better
than with macroadenoma i.e., 100% vs. 32%  but there were
limited number of cases with microadenoma (n=5).
Generally, the microadenomas do well postoperatively than
macroadenomas.26
During selective adenomectomy, pituitary function
is generally well preserved27 and preoperative suppression
also improves as a result of surgical removal of the tumour.
Ross and Wilson showed that only nine (5.2%) of 172
patients had postoperative deterioration of pituitary func-
tion.22 We observed that preoperatively four patients had
hypopituitarism which persisted postoperatively. In the
present study postoperative hypopituitarism was seen in sig-
nificant number of cases (20%).
In conclusion, the data reviewed showed that
acromegaly was seen at a much earlier age, more aggressive
disease was seen in younger age group, the outcome of sur-
gery was comparable to other studies and postoperative
panhypopituitarism was seen in significant number of
patients. The outcome in microadenoma was better than in
macroadenoma but the number of patients seen with
microadenoma was small. 
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